Showing results (1411-1420 of 1,436) with videos related to

Sort By:
Pageof 144
The New England Journal of Medicine|December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L Locke, David B Miklos, Caron A Jacobson, et al.
Blood|December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapyAnthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.
American Journal of Respiratory and Critical Care Medicine|March 15, 2023
Genetic Modifiers of Cystic Fibrosis Lung Disease Severity: Whole-Genome Analysis of 7,840 PatientsYi-Hui Zhou, Paul J Gallins, Rhonda G Pace, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Plos One|December 27, 2018
Seasonal changes in diet and chemical defense in the Climbing Mantella frog (Mantella laevigata)Nora A Moskowitz, Alexandre B Roland, Eva K Fischer, et al.
JCO Oncology Practice|February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
Clinical & Experimental Metastasis|June 1, 2004
A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasisJohn F Harms, Danny R Welch, Rajeev S Samant, et al.
Blood Advances|September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2024
Randomized Phase III SIERRA Trial of <sup>131</sup>I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AMLBoglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, et al.
Pageof 144